Please assess the completion status of the following clinical trial:

Trial Title: NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have one of the following clinical diagnoses for at least 3 months prior to screening a) schizophrenia or schizoaffective disorder; b) mood disorder; or c) gastrointestinal disorder (e.g., gastroparesis, gastroesophageal reflux disease)~* Have a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening.~* Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.~* Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.~* Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study.~* Female subjects must not be pregnant.~* Be in good general health and expected to complete the clinical study as designed.~* Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).~* Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.~* Have a negative alcohol breath test at screening and study start.~Exclusion Criteria:~* Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening.~* Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).~* Have a known history of neuroleptic malignant syndrome.~* Have a significant risk of suicidal or violent behavior.~* Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine.~* Receiving medication for the treatment of tardive dyskinesia.~* Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a history of positive result.~* Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.~* Have an allergy, hypersensitivity, or intolerance to tetrabenazine.~* Have had previous exposure with NBI-98854.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- NBI-98854 (Type: EXPERIMENTAL): Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).